Get the Stockscreener App
21.08
1.34%
0.2834
Caredx Inc stock is traded at $21.08, with a volume of 466.10K.
It is up +1.34% in the last 24 hours and up +8.20% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$20.80
Open:
$20.78
24h Volume:
466.10K
Relative Volume:
0.53
Market Cap:
$1.09B
Revenue:
$312.78M
Net Income/Loss:
$-143.56M
P/E Ratio:
-7.8377
EPS:
-2.69
Net Cash Flow:
$1.22M
1W Performance:
+4.35%
1M Performance:
+8.20%
6M Performance:
+64.80%
1Y Performance:
-6.53%
1-Day Range:
$20.35
$21.20
1-Week Range:
$19.90
$21.48
52-Week Range:
$10.96
$25.55
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
21.14 | 1.07B | 312.78M | -143.56M | 1.22M | -2.69 |
|
TMO
Thermo Fisher Scientific Inc
|
624.75 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.35 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
697.90 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.86 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.71 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-26-25 | Initiated | William Blair | Mkt Perform |
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
Can CareDx Inc deliver consistent dividendsDollar Strength & Advanced Swing Trade Entry Alerts - mfd.ru
Death Cross: Is CareDx Inc a play on infrastructure spendingCPI Data & AI Based Buy and Sell Signals - baoquankhu1.vn
CareDx CEO Hanna sells $412,222 in shares By Investing.com - Investing.com Nigeria
CareDx CEO Hanna sells $412,222 in shares - Investing.com
Insider Sell: Hanna John Walter JR Sells Shares of CareDx Inc (C - GuruFocus
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 19,280 Shares - MarketBeat
CareDx, Inc. (CDNA) Stock Analysis: A Healthcare Innovator With 4.66% Upside Potential - directorstalkinterviews.com
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 10,156 Shares - MarketBeat
Tech Rally: What is the dividend yield of CareDx IncJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Sentiment Review: Can CareDx Inc generate free cash flow2025 Winners & Losers & Community Verified Trade Alerts - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in CareDx, Inc. $CDNA - MarketBeat
CareDx (CDNA) Is Up 19.5% After Stronger-Than-Expected 2025 Revenue GuidanceHas The Bull Case Changed? - Sahm
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
CareDx (CDNA) Valuation Check After Strong Preliminary 2025 Revenue Guidance And Transplant+ Pipeline Progress - Sahm
Can CareDx Inc maintain sales growthJuly 2025 Short Interest & Expert Curated Trade Setups - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA) - The Globe and Mail
Implied Volatility Surging for CareDx Stock Options - sharewise.com
Aug Levels: Is AEYE stock forming a triangle patternRate Hike & Precise Entry and Exit Recommendations - baoquankhu1.vn
CareDx (CDNA) Is Up 9.4% After Strong 2025 Outlook And 10x Genomics Tie-UpHas The Bull Case Changed? - Yahoo Finance
CareDx reports 25% revenue growth in Q4, expects $380 million for 2025 - Investing.com Canada
CareDx (NASDAQ:CDNA) Trading 15.3% HigherTime to Buy? - MarketBeat
Caredx Provides Earnings Guidance Fourth Quarter and Full Year 2025 - marketscreener.com
Aug Wrap: Is CareDx Inc a play on infrastructure spendingStop Loss & Weekly High Return Stock Forecasts - baoquankhu1.vn
CareDx Preliminary Q4 Revenue Up 25% - Nasdaq
CareDx reports 25% revenue growth in Q4, expects $380 million for 2025 By Investing.com - Investing.com South Africa
CareDx's prelim Q4 revenue beats estimates on higher testing volumes - TradingView — Track All Markets
Transplant test maker CareDx reports 25% jump in late‑2025 revenue - Stock Titan
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The Joplin Globe
Whittier Daily News - FinancialContent
NeoGenomics, Inc. Announces Executive Changes - marketscreener.com
Profit Review: Can CareDx Inc stock continue upward trendJuly 2025 PostEarnings & Low Risk High Reward Ideas - moha.gov.vn
Why CareDx Inc stock is popular among millennialsGap Down & Verified Chart Pattern Signals - Улправда
Aug Opening: Can CareDx Inc stock continue upward trendJuly 2025 Momentum & Fast Exit/Entry Strategy Plans - Улправда
Can CareDx Inc stock hit record highs again2025 Earnings Surprises & Daily Stock Momentum Reports - Улправда
Dow Update: Will CareDx Inc (1K9) stock gain from lower interest ratesJuly 2025 Macro Moves & AI Enhanced Trading Alerts - Улправда
Why retail investors pile into CareDx Inc stockJuly 2025 Fed Impact & Capital Protection Trade Alerts - Улправда
Why CareDx Inc stock is in analyst buy zoneMarket Activity Summary & Verified Momentum Stock Ideas - ulpravda.ru
CareDx (NASDAQ:CDNA) Trading Down 7.9%What's Next? - MarketBeat
Can CareDx Inc stock continue upward trendShare Buyback & Entry Point Strategy Guides - ulpravda.ru
CareDx and 10x Genomics partner on transplant rejection research By Investing.com - Investing.com Nigeria
CareDx (CDNA) director Michael Goldberg receives 1,492-share equity grant - Stock Titan
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response - BioSpace
Assessing CareDx (CDNA) Valuation After ImmuneScape Multiomics Collaboration With 10x Genomics - Sahm
CareDx, 10x Genomics Establish Multiomics Research Initiative - Contract Pharma
CareDx, 10x Genomics Launch Platform to Study Transplant Rejection and Drug Response - marketscreener.com
CareDx and 10x Genomics partner on transplant rejection research - Investing.com
CareDx, Inc. and 10x Genomics to Launch ImmuneScapeA Multiomics Research Platform to Decode Transplant Rejection and Drug Response - marketscreener.com
User - FinancialContent
CareDx wins preliminary court approval for derivative settlement - MSN
CareDx (NASDAQ:CDNA) Shares Gap DownHere's Why - MarketBeat
Craig-Hallum downgrades CareDx stock rating to Hold from Buy By Investing.com - Investing.com South Africa
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Caredx Inc Stock (CDNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hanna John Walter JR | President and CEO |
Jan 21 '26 |
Sale |
21.00 |
200 |
4,200 |
616,685 |
| Hanna John Walter JR | President and CEO |
Jan 15 '26 |
Sale |
21.05 |
10,156 |
213,804 |
616,885 |
0.95%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):